Нам исполнилось уже 3 года! Руководители компании благодарны всем партнерам нашей компании, которые все эти годы были с нами и трудились ради достижения высокой цели — стать лучшими.
За этот небольшой период времени мы приобрели истинных друзей, которые всегда поддерживали нас и помогали нам. Мы хотим поблагодарить их за это и надеемся на долгосрочное сотрудничество еще не один год!
Мы надеемся, что и впредь нашей компании будет сопутствовать успех и удача! Поздравляем с этим замечательным праздничным днем Всех партнеров компании, группы трейдеров, брокеров, клиентов и трейдеров которые так или иначе имеют отношение к нашей компании. Спасибо, что Вы есть у нас, доверяете нам и у нас сложились не только партнерские отношения, но и дружеские.
В связи с этим, компания объявляет запуск акции:
Всем новым клиентам компании торговый терминал Такион — Бесплатно весь декабрь и январь!
Комиссия для новых клиентов до 1 февраля — 3$ за 1 000 акций на терминале Takion
Так же мы сделали исключение в этот праздник и для наших клиентов:
При переходе с торгового терминала Fusion или Sterling на Takion до 1 февраля комиссия в 3$ за 1 000 акций
Для всех замороженных аккаунтов, при активации, пополнении счета от 500 долларов и переходе на торговый терминал Takion комиссия до 1 февраля — 3$ за 1 000 акций
Время действия акции ограничено, торопитесь воспользоваться торговыми условиями! Подробности можно узнать у наших менеджеров.
SPY резко идет вверх
Ближайший уровень поддержки по SPY – 205.50 уровень сопротивления – 207.50
WLL,ERX смотрим на откат с открытия
RCPT продажа от вчерашнего хая дня
DDS продажа ниже 120
WSM продажа от 76
EXP выше 92 покупка, ниже продажа
LL продажа от 59
ASPS смотрим на покупку
GMCR покупка от 144
GPRO смотрим на покупку
Новостные акции:
SPLK, ROST, FL, GME, ARUN, LRAD, BBD, PBR, WLT, CLF, VALE. RIO. BHP, SSL, SFUN, BID, BABA, TRN, BBY SPY на максимуме перед открытием
Ближайший уровень поддержки по SPY – 204.00 уровень сопротивления – 204.25
AGIO продажа от 82, выше покупка
CHTR смотрим на покупку
TWC покупка выше 137
RYN смотрим на продажу
Новостные акции:
RAX, QIWI, ANIK, IMAX, RIO, VALE, BABA SPY третий день стоит во флете
Ближайший уровень поддержки по SPY – 201.00 уровень сопротивления – 202.50
Gapping up/down: NOK +9%, CAT +4% and GM +2% after earnings, BABA +1% after initiation at Overweight; YELP -12%, CAB -10%, CTXS -6% and UA -4% after earnings Price: null Change: null
Gapping up
In reaction to strong earnings/guidance: JAKK +16.2%, EGHT +13.4%, SCSS +13.3%, TSCO +12.6%, INFN +12.6%, DAN +9.8%, NOK +8.7%, ACTG +8.3%, LCI +7.3%, PLCM +6.2%, LOGI +5.7%, YNDX +5.2%, JNS +5.2%, MKTO +4.5%, DO +4.4%, CAT +4.4%, ORAN +4.2%, SLM +4%, ORLY +3.9%, MLNX +3.5%, SHLM +3.3%, (following late move lower), ALXN +3%, FTNT +2.9%, LUV +2.7%, MMM +2.2%, NXPI +2.1%, SFG +2%, CSH +2%, BBW +2%, UNP +1.9%, NOW +1.8%, GM +1.7%, DMRC +1.6%, AB +1.6%, JBLU +1.5%, SGMO +1.4%, ORRF +1.3%, CAM +1.2%, RTN +1.1%, CMCSA +1%, CHKP +0.9%
M&A news: BRP +21.3% (Brookfield Asset Mgmt proposes to acquire 30% of Brookfield Residential Properties (BRP) not currently owned for $23.00/share), WWAV +7.2% (WhiteWave Foods or Boulder Brands (BDBD) may be possible takeover targets, according to Bloomberg real M&A column), PETM +3.1% (has received takeover interest from KKR (KKR) and outer PE firms, according to reports)
Other news: CYTX +50% (received FDA approval to resume ATHENA trial enrollment), VIMC +8.4% (announces $29.2 million contract win in Chenzhou city of Hunan province), KNDI +5% (still checking), PH +4.5% (increases quarterly dividend 31 percent and authorizes the repurchase of up to 35 million shares), RGLS +3.3% (after doubling yesterday), ERIC +3% (in symp with NOK), GPRO +2.9% (still checking), ING +2.1% (in symp with CS), BBRY +2.1% (trading higher, may be on NOK earnings, but also a story that co is unlikely to be acquired by Lenovo (LNVGY), according to reports), CSH +2% (approved the spin-off of its E-Commerce Division, Enova International, Inc., into an independent and separate publicly traded company), STX +1.7% (raises targeted annual dividend), UBS +1.7% (in symp with CS), CPXX +1.7% (pricing of a $12.9 million public offering of common stock at $1.95/unit and warrants to purchase common stock at $3.58/whole share and will have a term of five years), TWTR +1.5% (presented at Mobile Developer conf yday), V +1.3% (declared a quarterly dividend in the aggregate amount of $0.48 per share, a 20% increase), TSLA +1.2% (to enter Australia market, accoridng to reports), KMX +1% (raises share repurchase authorization by $2 bln), LYG +0.8% (plans to eliminate 9000 jobs, according to reports)
Analyst comments: ALU +6% (upgraded to Hold from Underperform at Jefferies), LUX +2.3% (upgraded to Buy from Hold at Berenberg), DOW +2% (upgraded to Buy from Hold at Deutsche Bank), BABA +1.1% (initiated with an Overweight at Barclays), ABBV +1% (resumed with a Overweight at JP Morgan), GSK +0.9% (upgraded to Overweight from Equal Weight at Barclays)
Gapping down
In reaction to disappointing earnings/guidance: AIRM -24.3%, YELP -12.5%, CAB -9.6%, CLB -6.8%, CTXS -6.6%, IPCM -6.2%, AWH -4.7%, (light volume), CAKE -4.5%, VAR -4.3%, ACAT -4%, UA -4%, OTEX -3.9%, DNKN -3.8%, TER -2.2%, SUSQ -2.1%, UN -1.9%, GOL -1.7%, LRCX -1.5%, WFT -1.5%, CA -1.3%, T -1%, PCP -1%, CCE -0.8%
Other news: ADHD -14.1% ( released a presentation with updated clinical trial results of Metadoxine Extended Release for the treatment of ADHD), FREE -9.1% (filed for 17,500,000 shares common stock, offering by selling stockholder), PT -5.4% (still checking), NMFC -3.8% (commences offering of 5,000,000 shares of common stock), WYY -3.7% (prices public offering of 6,896,552 shares of common stock at $1.45/share), ZAZA -1% (following 40% move higher yesterday), ISNS -0.9% (following 30% move higher yesterday), SPEX -0.8% (provides litigation update)
Analyst comments: MDCO -1.5% (downgraded to Neutral from Buy at BofA/Merrill)
Gapping up/down: ILMN +9%, HOG +8%, TXN and AAPL +2% after earnings, PANW +1.5% after target raise; HAL +1% after upgrade; RMBS, -7%, ARMH -6%, KO -3% and MCD -2% after earnings, IBM -1% after dg Price: null Change: null
Gapping up
In reaction to strong earnings/guidance: LXK +11%, ILMN +8.8%, HOG +7.8%, WERN +4.6%, CE +4.1%, CSL +3.7%, HLX +3.6%, WAT +2.5%, TXN +2.4%, AAPL +2.3%, AOS +2.3%, MBCN +2.2%, UTX +2%, STLD +1.9%, CDNS +1.1%, TRV +1.1%, ELS +0.9%, KMB +0.9%, CP +0.8%
M&A news: ACT +1.5% (Actavis and Sanofi (SNY) may be among bidders for Omega Pharma, according to reports).
Select EU financial related names showing strength: LYG +2.7%, RBS +2.5%, ING +2.3%, DB +0.8%.
Select metals/mining stocks trading higher: X 2.3%, MT 1.8%, AG 1.5%, GFI -0.5%.
Select oil/gas related names showing strength: STO +2.7%, SDRL +2.6%, BP +1.6%
Other news: NEON +22% (signs technology development agreement with global tier one printer OEM ), SGYP +13.1% (presents positive Phase 2b study results for Plecanatide in patients with irritable bowel syndrome), SCOK +5.6% (cont momentum), NXPI +2.6% (following TXN / AAPL results), GSAT +2.6% (co reiterated value of its spectrum assets; believes Kerrisdale continues to 'distort facts in attempt to undermine the benefits of TLPS'), TKMR +2.4% (cont momentum), CRUS +2.2% (following AAPL results), ABBV +2% (announced new $5 bln stock repurchase and increases dividend), BRCM +1.9% (following TXN results), RCL +1.9% (cont strength following yday's advance), TSL +1.7% (still checking), RFMD +1.5% (following AAPL results — component supplier), ACT +1.5% (Actavis and Sanofi (SNY) may be among bidders for Omega Pharma, according to reports), MU +1.4% (following TXN results), SUNE +1.4% (still checking), CCL +1.3% (cont strength following yday's advance), MGM +1.3% (still checking), MPW +1% (announced more than $1 billion in new real estate investments; expected to be accretive to normalized FFO by $0.09 — $0.12 per share), JEC +1% (awarded remediation task order for Eielson Air Force Base, Alaska worth ~$18.7 mln)
Analyst comments: POST +3.2% (upgraded to Buy from Neutral at Goldman), KITE +1.7% (target raised to $45 at Stifel), PANW +1.5% (target raised to $115 at Oppenheimer), COG +1.2% (upgraded to Outperform from Mkt Perform at Bernstein), HAL +1.2% (upgraded to Buy from Neutral at Guggenheim), EOG +0.5% (upgraded to Buy from Neutral at Guggenheim)
Gapping down
In reaction to disappointing earnings/guidance: GLF -8%, RMBS -6.9%, KALU -6.8%, UCTT -6.3%, ARMH -5.9%, APOL -5.4%, CMG -5.2%, XRS -3.3%, KO -3.1%, PKG -2.5%, CYS -1.6%, RCII -1.6%, LMT -1.6%, MCD -1.5%, IHG -1%, ZION -0.9%, BRO -0.9%, VZ -0.8%,.
Select Brazil related names showing weakness: OIBR -8.2%, PBR -7.7% SID -3.5%, VIV -2.8%, ELP -2.5%, GGB -2.2%, SBS -2.1%, VALE -1.7%, ABEV -1.4%.
Other news: RNO -42.8% (announces Q3 distribution of $0.05 per unit, lowered from previous quarter distribution of $0.445 per unit; co redoubling its cost cutting efforts due to weak coal markets), IBIO -20.2% (cont volatility), CVM -17.6% (announces proposed public offering of Common Stock; terms not disclosed), OMER -15% (provides update on PDE10 inhibitor program; enrollment in Huntington's Trial suspended pending further assessment of preclinical data), PT -8.3% (still checking, but Oi SA announces liquidation of assets will have no impact on the business combination with Portugal Telecom), LAKE -2.9% (cont weakness), TLLP -2% (prices upsized public offering of 20 mln common units at $57.47 per unit), SPLS -1.8% (spokesman has indicated company is investigating possible data breach, according to reports), ENTA -1.7% (provides update on its collaboration agreement with AbbVie (ABBV); co-development option on next-generation Protease Inhibitor ABT-493 Not Exercised, net sales allocations for ABT-450-containing regimens finalized), PHG -1.7% (cont weakness), REN -1.4% (provides operation update: Three Permian Basin horizontal wells averaged 1,300 Boe per day on peak 24-hour IP tests), GSK -1.3% (still checking), TRN -1.2% (late sell-off on guardrails ruling; confirms $175 mln in damages at jury trial)
Analyst comments: PHG -1.7% (downgraded to Neutral from Buy at UBS), IBM -0.7% (downgraded to Hold from Buy at Evercore; target lowered to $170 at RBC Capital Mkts), IRC -0.6% (downgraded to Underperform from Neutral at BofA/Merrill), ED -0.4% (downgraded to Underweight at Morgan Stanley)
Gapping up/down: MS and GE +4% after earnings, NVS +2% after NICE draft guidance, AKS and SUNE +6% after upgrades; URBN -13%, SNDK -3% and GOOG -1% after earnings Price: null Change: null
Gapping up
Briefing note: With S&P futures up over 1% in the pre-market, many stocks are gapping higher that are not listed.
In reaction to strong earnings/guidance: QLGC +10.1%, (also Announces Approval of a $100 million Stock Repurchase Program), FHN +6.1%, XLNX +5.7%, CPHD +4.1%, MS +3.8%, GE +3.7%, WDFC +3%, SLB +2.6%, HON +1.9%
M&A news: HZNP +1.9% (announces acquisition of U.S. rights to PENNSAID 2% From Nuvo Research Inc. for $45 mln in cash), EXP +1.8% (to acquire CRS Proppants for ~$225 mln)
Select EU related names showing strength: ING +3.3%, ALU +3%, ASML +2.3%, CS +1.8%
Select Ebola related stocks trading higher: IBIO +11.6%, NLNK +5.1%, LAKE +4.9%
Select oil/gas related names showing strength: PBR +4.1%, STO +3.3%, SDRL +2.9%, HAL +2.2%
Other news: AMPE +16.3% (announces results of the open label portion of the multiple intra-articular injections study of Ampion), SRPT +9.7% (announces publication of Ebola and Marburg Phase I Clinical Study results in antimicrobial agents and chemotherapy), FMI +9.1% (announced an agreement to enhance precision medicine options for Priority Health members with advanced cancers, also upgraded to Outperform from Mkt Perform at William Blair), BEAT +7.8% (announces reinstatement of Cigna's coverage of Mobile Cardiac Monitoring Services), HCLP +6.1% (announced 9% increase in third quarter 2014 distribution to $0.625 per unit), PPC +2.9% (following weakness in poultry names on SAFM Investor Day comments), NVS +1.9% (NICE has issued final draft guidance proposing to recommend imatinib, also known as Glivec and made by NVS ), X +1.8% (may be in symp with AKS upgrade),.
Analyst comments: AKS +6.1% (upgraded to Buy from Neutral at Nomura), SUNE +5.7% (upgraded to Outperform from Mkt Perform at Cowen), EJ +5.6% (upgraded to Buy from Neutral at Goldman), NBR +2.2% (upgraded to Buy from Neutral at UBS), GS +1.5% (upgraded to Outperform from Mkt Perform at Keefe Bruyette), ISRG +0.9% (upgraded to Outperform at Leerink Partners)
Gapping down
In reaction to disappointing earnings/guidance: URBN -13.6%, (reports Q3 negative comparable retail segment net sale has continued quarter-to-date; gross profit margin may deleverage at a rate greater than during 1H), SNDK -2.8%, ATHN -2%, AMD -1.1%, GOOG -0.9%, COF -0.7%
M&A news: CF -3.9% (announced the termination of merger discussions with Yara International)
Other news: RPRX -40.6% (announces upcoming FDA meeting to be Type C meeting instead of Type B Pre-NDA meeting), CCL -3.4% (Health Care worker who may have handled Thomas Duncan's Ebola lab specimens has been isolated on CCL ship, according to reports), RCL -3% (in symp with CCL news), ANF -1.7% (following URBN guidance), AEO -1.2% (following URBN guidance), EARN -1.1% (co requested the withdrawal of its registration statement on Form S-11; intends to register on Form S-3)
Gapping up/downs: BGG +2% after earnings, CHK +6% after asset sale; NFLX -25% EBAY -3%, DAL and GS -2% after earnings, RIO -3% after dg Price: null Change: null
Gapping up
In reaction to strong earnings/guidance: HCA +4.9%, UMPQ +3.5%, BGG +2.4%, HNI +2.3%, TSM +1.8%, URI +1.7%, NTCT +1.3%, KMP +0.8%
Select Ebola related names showing strength: CMRX +6%, SRPT +2.3%, LAKE +0.6%
Other news: EGLE +120.6% (completed financial restructuring; all existing equity interests cancelled), MSO +16.8% (Martha Stewart confirms multi-year media partnership with Meredith Corporation (MDP); will have an immediate impact on Operating Income), CVV +11.5% ((reported $27.5 mln in new orders through Q3, representing an increase of ~239% in new orders from prior year),), VIMC +6.2% (announced $39.80 mln contract wins in Taiyuan City of Shanxi province), APP +6% (seeing reports that co has made an interest payment on its bonds), CHK +5.9% (announces sale of Southern Marcellus and Utica Shale assets for proceeds of $5.375 bln), ANV +5.4% (announced preliminary Q3 production and sales: 49,630 ounces of gold produced vs 52,198 in prior year), ATEA +2.4% (filed timely appeal, which will stay the suspension of trading of its common stock on NASDAQ, pending the decision by a NASDAQ hearings panel), CPA +2.4% (announced monthly traffic statistics for September 2014: System-wde passenger traffic increased 1.9% yoy)
Analyst comments: SBGL +5.5% (upgraded to Neutral from Sell at UBS), BMRN +0.2% (initiated with a Buy at Sun Trust Rbsn Humphrey)
Gapping down
Briefing note: With the S&P Futures down nearly 1% in the pre-market, many stocks are gapping lower that are not listed.
In reaction to disappointing earnings/guidance: NFLX -25%, EXTR -22.9%, BHI -11.7%, ZHNE -6.3%, MAT -4.4%, EBAY -3.3%, BX -2.9%, DAL -2.7%, GS -2.4%, PM -1.8%, BBT -1.6%, KMI -1.5%, BAX -1.5%, AXP -1.4%, FCS -0.7%, UNH -0.5%
Select financial related names showing weakness: DB -5.3%, ING -5.1%, SAN -4.8%, CS -4.5%, BCS -3.9%, C -2.2%, JPM -1.9%, WFC -1.7%, BAC -1.5%
Select energy stocks trading lower: STO -6.1%, HAL -5.2%, RDS.A -4.3%, TOT -3.8%, BP -2.8%
Select EU related names showing early weakness: ALU -5.7%, UBS -4.6%, MT -4.4%, DEG -4.4%, ORAN -4.3%, ASML -4.2%, PHG -4.1%, SAP -3.6%, YY -3.3%, VOD -3.2%, NVS -2.2%
Other news: INSY -8.8% (receives DEA approval to produce pharmaceutical Cannabidiol; provides update on status of cannabinoid program ), ESPR -8.6% (prices 4.25 mln shares of common stock at $20.00 per share), TTPH -6.2% ( announces proposed public offering of common stock), GWPH -6.1% (cont weakness), SHLD -4.9% (announces commencement of rights offering), JKS -4.5% (signs 200 MW PV project development agreement with Government of Shicheng County in Jiangxi Province), RIG -4.4% (provided fleet status report: total value of new contracts since the September 22, 2014 update is ~$610 mln), AEG -3.9% (announces agreement to sell its Canadian Life Insurance Business for CAD$600 mln; expected to result in a book loss of ~CAD$1.2 bln), MHR -3.7% (closes on the previously announced definitive agreement to sell certain non-core assets), CSUN -3.6% (announces CFO Mr. Yongfei Chen's resignation and appoints Mr. Shiliang Guo as acting CFO), AMZN -3% (following EBAY results), BHP -2.2% (trading in symp with RIO)
Analyst comments: CGG -8.4% (downgraded to Reduce from Neutral at Nomura), SDRL -4.5% (downgraded to Reduce from Neutral at Nomura), AKAM -3.5% (downgraded to Market Perform from Outperform at Wells Fargo), RIO -3.2% (downgraded to Market Perform at Cowen ), DIS -1.8% (downgraded to Neutral from Buy at Guggenheim).
Gapping up/down: CSX +2% and BAC +1% after earnings, CSRE +30% after merger with QCOM, Ebola names trading higher; LLTC -4% and INTC -1% after earnings, metals/miners trading lower, Price: null Change: null
Gapping up
In reaction to strong earnings/guidance: SURG +4.7%, MTG +2.3%, CSX +1.8%, HPQ +1.8%, NHTC +1.5%, BLK +1.4%, BAC +0.7%, PNC +0.5%
M&A news: CSRE +30.5% (Qualcomm (QCOM) to acquire CSR for ~$2.5 bln)
Select Ebola related names showing strength: APT +24.3%, LAKE +16.2%, IBIO +10%, HEB +6.3%, NLNK +6.1%, CERS +3.7%, CMRX +3.3%, SRPT +3.1%, TKMR +3%, INO +2.1%, NNVC +1.4%
Other news: ANN +8.2% (Golden Gate Capital files amended 13D with Confidentiality Agreement dated today Oct 14), NAVB +7.3% (FDA approves expanded use of Navidea's Lymphoseek for lymphatic mapping in solid tumors), GTAT +4.9% (Apple (AAPL) wants to secretly challenge GTAT bankruptcy, according to reports), MPO +4.3% (provides hedging update; 1212K barrels/day through 2Q15 at avg. ~$90/bbl), STRP +1.2% (after 18% move higher on earnings yesterday), SSRI +1.1% (analyst tour at Marigold highlights life of mine plan and exploration results), AMD +1.1% (in symp with INTC earnings), CCL +0.9% (Carnival and largest Chinese Shipyard sign Memo of Understanding aimed at growing the cruise industry in China),.
Analyst comments: PTEN +2% (initiated with a Buy at Citigroup), UNFI +1.9% (upgraded to Overweight from Neutral at Piper Jaffray), EXXI +1.5% (upgraded to Buy from Neutral at Global Hunter Securities), SWIR +1.1% (initiated with a Outperform at Northland Capital), CBS +1.1% (upgraded to Buy from Neutral at Citigroup), AMAT +0.8% (upgraded to Buy from Neutral at BofA/Merrill), RAX +0.6% (upgraded to Outperform from Sell at Credit Agricole), HST +0.5% (upgraded to Overweight from Equal Weight at Barclays)
Gapping down
In reaction to disappointing earnings/guidance: LLTC -3.7%, KEY -2.8%, INTC -1.1%, KTCC -1.1%
M&A news: SHPG -25.9% (notice to Shire Of AbbVie (ABBV) Board intention to reconsider recommendation), ABBV -3.9% (Announcement of notice to Shire Of AbbVie (ABBV) Board intention to reconsider recommendation), QCOM -0.5% (Qualcomm (QCOM) to acquire CSR for ~$2.5 bln)
Select EU related names showing weakness: SAN -3.5%, ALU -3.2%, BCS -2.7%, ALV -2.6%, NOK -2.5%, UBS -1.8%
Other news: CNET -10.3% (following 60%+ move higher yesterday), GWPH -4.9% (cont weakness), STAG -4.3% (announces public offering of 5 mln shares of common stock), NSPH -4.2% (following yesterday's 40% decline), STO -3.9% (president and CEO Helge Lund resigns), SNN -3.6% (likely attributed to tax inversion rules and fall out from SHPG/ABBV merger news), AZN -2.6% (likely attributed to tax inversion rules and fall out from SHPG/ABBV merger news), CUBE -2.2% (announces public offering of 6.5 mln common shares of beneficial interest), ESPR -1.4% (announces proposed public offering of $85 mln of common stock)
Analyst comments: RIG -2.2% (initiated with a Sell at ISI Group), OXY -0.6% (downgraded to Neutral from Outperform at Credit Suisse)
Gapping up/down: APL and ATLS +13% on M&A related news; Ebola related names trading higher, SPLK +2% on upgrade; LAD -10% and GY -3% after earnings, JCP and CLF -1% on dg's Price: null Change: null
Gapping up
In reaction to strong earnings/guidance: MDXG +4.3%
M&A news: APL +12.8% (Targa Resources Partners and Targa Resources Corp. (TRGP) to acquire Atlas Pipeline Partners, L.P. (APL) and Atlas Energy, L.P. (ATLS)), ATLS +12.5%, CSX +9.2% (was approached for M&A deal with Canadian Pacific (CP) but CSX refused it, according to reports), TRGP +1.9%.
Select EU related names showing strength: NOK +2.3%, HSBC +2.1%, SAN +1.9%, YNDX +1.4%, RBS +1.1%, DB +0.9%
Select Ebola related stocks trading higher: IBIO +78.9% (outpacing strength seen this morning in most Ebola related names; checking around for company specific catalyst), HEB +20.6%, APT +18.7% (masks), LAKE +17.5% (masks), NLNK +4.7%, TKMR +4.1%, MLNX +2.2%, INO +1.1%, BCRX +0.7%, SIGA +0.7%
Select oil/gas related names showing strength: PBR +6.7%, SDRL +5.7%, TOT +1.6%, RIG +1.4%
Other news: DRL +66.4% (wins in Puerto Rico tax case), AHPI +7.6% (cont momentum), SHLD +4.9% (Kmart investigating payment system intrusion), AIXG +4.8% (Allianz Global Investors discloses 10.03% passive stake in 13G filing), KSU +2.6% (CSX peer), PXD +2.5% (Reliance Industries may sell PXD joint venture for $4.5 bln, according to reports), STO +1.5% (sells 15.5% share in Shah Deniz to Petronas for $2.2 bln), TASR +1.4% (announced four international orders — Australia, France, the UK, and Poland — for TASER brand next generation Smart Weapons).
Analyst comments: FOMX +8.3% (initiated with an Overweight at Barclays; initiated with a Outperform at Oppenheimer), GOLD +4.8% (upgraded to Buy from Neutral at UBS), TKAI +3.2% (initiated with an Outperform at William Blair), PRQR +3.2% (initiated with a Buy at H.C. Wainwright), SPWR +3% (upgraded to Outperform from Mkt Perform at Raymond James), SPLK +2.4% (upgraded to Outperform from Mkt Perform at William Blair), AZN +2.3% (upgraded to Buy from Hold at Jefferies), INFY +2% (upgraded to Buy form Hold at Deutsche Bank), TILE +2% (upgraded to Overweight from Equal Weight at Barclays), OUTR +1.9% (upgraded to Neutral from Sell at B. Riley & Co), SFUN +1.4% (upgraded to Buy from Hold at Deutsche Bank), TMUS +0.7% (upgraded to Outperform from Neutral at Macquarie)
Gapping down
In reaction to disappointing earnings/guidance: LAD -10.5%, GY -2.9%
M&A news: DG -1.2% (receives second request from FTC, as expected, regarding proposed acquisition of Family Dollar (FDO))
Other news: GTAT -23.5% (cont vol pre-mkt), LAD -10.5% (still checking), SFLY -7.9% (PE firm Silver Lake abandons attempt to acquire and combine Shutterly and Snapfish, according to reports), LUX -7.2% (Enrico Cavatorta to submit to the Board his resignation as CEO, also downgraded to Neutral from Buy at Citigroup), GPRO -1.8% (cont vol pre-mket), MBLY -1.2% (cautious Barrons mention)
Analyst comments: STM -2.3% (downgraded to Neutral from Overweight at JP Morgan, downgraded to Underweight from Equal-Weight at Morgan Stanley), NGD -1.8% (downgraded to Neutral from Overweight at JP Morgan), JCI -1.2% (downgraded to Outperform at RBC Capital Mkts), CLF -1% (downgraded to Neutral from Overweight at JP Morgan), JCP -1% (downgraded to Sell from Neutral at UBS), CME -0.5% (downgraded to Market Perform from Outperform at Wells Fargo)
Gapping up/down: INFY +5% after earnings, EXAX +36% after positive CMS determination over Cologuard; MCHP -11%, MTW -9%, and JNPR -7% after earnings, Semis, oil and gold stocks trading lower Price: null Change: null
Gapping up
In reaction to strong earnings/guidance: INFY +5.6%, HELE +3%, PLUG +2.7%
Other news: EXAS +35.8% (positive CMS determination over Cologuard), APT +26% (following 27% move higher yesterday with ongoing Ebola fears), SCMP +19.2% (Sucampo Announces Settlement Agreement That Resolves Patent Litigation in U.S. Related to AMITIZA), ALXA +16.8% (provided update on ADASUVE U.S. Commercial Progress; Alexza shipped 32,278 units in the third quarter, completing the ADASUVE initial product inventory stocking), CVEO +12.6% (Greenlight capital discloses 9.99% active stake in 13D filing), STV +6.9% (cont volatility pre-mkt), ISIS +5.3% (reports data from ISIS-SMN Rx Phase 2 studies in infants and children with spinal muscular atrophy), VNET +4.7% (establishes joint venture with Foxconn (FXCNY)), ARIA +3.7% (announced that Pharmacovigilance Risk Assessment Committee of EMA concluded review of Iclusig and has recommended that Iclusig continue to be used in Europe in accordance with its already approved indication), BX +2.7% (planning advisory spin-off, according to reports), ECOL +2.5% (to replace MEAS in the S&P SmallCap 600), OXLC +2.1% (adopted repurchase program of up to $35 mln worth of common stock), KGJI +1.6% (announces initial shipment of 24-karat gold jewelry product samples to Middle East)
Analyst comments: NDLS +0.9% (initiated with an Outperform at BMO Capital Mkts ), WDC +0.7% (initiated with a Buy at Jefferies), NRP +0.7% (upgraded to Outperform from Market Perform at Wells Fargo), BUD +0.5% (added to Conviction Buy List at Goldman)
Gapping down
In reaction to disappointing earnings/guidance: PKT -25.1%, VOXX -16.4%, SZMK -13.9%, MCHP -11.1%, KN -10.8%, MTW -8.9%, JNPR -7%, JOEZ -5%, FDO -1%
Select metals/mining stocks trading lower: CVE -3.3%, RIO -2.2%, GOLD -1.9%, AU -1.2%, GFI -1%
Select oil/gas related names showing early weakness: SDRL -2.5%, STO -2.2%, BHP -2.1%, TOT -1.7%, RIG -1.6%, HAL -0.4%
Other news: GTAT -29.5% (reportedly looking to close down its saphire business, according to court documents), TSLA -6.2% (following run-up into Model D event, also neg mention on Mad Money), MBLY -4.8% (news that new Tesla (TSLA) Model D will have self driving features), TKMR -3.4% (cont volatility), THLD -2.3% (disclosed that it has licensed rights to a development program from the University of Auckland based on the clinical-stage oncology compound Hypoxin; co expects to initiate a Phase 2 study of Hypoxin), RDS.A -2.3% (still checking), PTCT -2.3% (prices 3 mln shares of common stock at $36.25), SM -1.9% (sees Q3 production of 13.1 MMBOE, or 142.5 MBOE/d, at low end of previously provided guidance), SYMC -1.6% (announces new strategy to fuel growth and plans to separate into two public companies), GPRO -1.3% (founder Silicon Valley Community Foundation filed 13D), YHOO -1.2% (still checking), AMGN -1.1% (BiTE Immunotherapy Blinatumomab receives FDA Priority Review designation in acute lymphoblastic leukemia)
Analyst comments: BDSI -3.4% (downgraded to Hold from Buy at ROTH Capital), NDSN -3.4% (downgraded to Hold from Buy at BB&T Capital Mkts), GRPN -3.1% (downgraded to Sell from Equal Weight at Evercore), JCP -2.5% (downgraded to Sell at Maxim Group), ICLR -1.8% (downgraded to Neutral from Buy at ISI Group), BTI -1.2% (downgraded to Sell from Neutral at Goldman)
Поздравляем всех с началом сезона отчетов. Вчера после закрытия рынка отчиталась положительно Alcoa Inc. Инвесторы могут положительно настроиться на рост рынка в ближайшие дни.
Alcoa — американская металлургическая фирма, 3-ий по величине производитель алюминия. Трехмесячный результат о деятельности данной фирмы, кой выходит 8 октября окажет мощное воздействие на цену акций.
GILD продажа от 109
AMGN продажа от 140
SSO продажа от 117
GOLD продажа ниже 70
URI покупка выше 103
DUST смотрим на лонг
Gapping up/down: RT +18% and AA +1.6% after earnings; AUXL +11% after merger ENDP, AGN +2.4% after upgrade; GPS -10% after guiding and CEO transition news, VOD -3% after dg Price: null Change: null
Gapping up
In reaction to strong earnings/guidance/SSS: RT +18.2%, DRWI +7.7%, EXAR +7.7%, LB +2.9%, AGN +2.4%, ZUMZ +1.8%, AA +1.6%, PEP +1.6%
M&A news: AUXL +10.7% (Endo (ENDP) to acquire Auxilium Pharmaceuticals in a cash and stock transaction for ~$2.6 bln, or $33.25 per share)
Other news: SFXE +10.1% (announces that Chairman and CEO Robert F.X. Sillerman completed the purchase of 575k shares today), GTAT +10% (cont volatility), UAL +4.7% (reported September 2014 consolidated traffic decreased 0.2%, consolidated capacity decreased 0.4%), BLDP +4.4% (Ballard Power announces multi-year fuel cell supply agreement with Plug Power (PLUG) for forklift market), CGG +3.3% (reports vessel utilization and fleet allocation updates for third quarter 2014), NUAN +1.9% (rumors on Carl Icahn tweet — potential acquistion target), PLUG +1.3% (Ballard Power announces multi-year fuel cell supply agreement with Plug Power (PLUG) for forklift market), GNC +1.3% (positive mention on Wednesday's Mad Money)
Analyst comments: UAL +4.7% (added to Global Focus list at Credit Suisse), LPSN +2.6% (upgraded to Outperform from Neutral at Credit Suisse), AGN +2.4% (initiated with a Buy at Deutsche Bank), UTI +0.9% (upgraded to Outperform from Market Perform at Wells Fargo), TSLA +0.8% (ahead of D-day event, also added to Global Focus list at Credit Suisse), ROYT +0.8% (upgraded to Buy at Stifel), JCP +0.6% (Hearing defended at Piper Jaffray--reits Overweight rating), IIVI +0.6% (upgraded to Buy at DA Davidson)
Gapping down
In reaction to disappointing earnings/guidance: ARCW -18%, KFX -14.8%, GPS -9.7%, (also announces CEO transition news), EOPN -8.9%, DEST -1.4%,.
M&A news: ENDP -0.7% (Endo to acquire Auxilium Pharmaceuticals)
Select financial related names showing weakness: DB -3.2%, BCS -2.7%, SAN -2.7%, RBS -2%, HSBC -1.8%, LYG -1.4%
Select oil/gas related names showing early weakness: TOT -2.7%, RDS.A -2.4%, BP -1.4%, STO -1.3%, STO -1.3%, RIG -1%
Other news: PT -4.4% (still checking), ARWR -3.8% (higher following Deutsche Bank analyst appearance on CNBC defending the company, said today's sell off was over done), ONTX -3.2% (co filed for a $100 mln mixed securities shelf offering; co also filed for a 228,647 share common stock offering by selling shareholders), STV -2.2% (disclosed further update on its asset restructuring), X -0.8% (CAD $ 185 mln debtor financing facility approved, according to reports), TWTR -0.7% (Twitter's exec Vivian Schiller to leave the company with part of media consolidation, according to reports)
Analyst comments: HUB.B -5% (downgraded to Perform at Oppenheimer), ARWR -3.8% (downgraded to Sector Perform at RBC Capital Mkts), VOD -3.1% (downgraded to Reduce from Neutral at Nomura), ERIC -1.9% (reinstated with a Underperform at BofA/Merrill)
Gapping up/down: COST +2% and YUM +1% after earnings, COTY +4% after upgrade; SAVE -3% and MON -2% after earnings/guidance, SAP -3% after reports of Job freeze, GPRO -2% after dg Price: null Change: null
Gapping up
In reaction to strong earnings/guidance: COST +2.4%, YUM +1.3%
M&A news: TST +5% (to acquire BoardEx for ~$21 mln), SYMC +3.4% (may consider splitting up security and storage units, according to reports), AGN +1.9% (VRX and Pershing Square intend to increase bid for co), VRX +1.4% (co and Pershing Square intend to increase bid for Allergan (AGN)
Select financial related names showing strength: NBG +2%, ING +1.4%, SAN +1.4%, UBS +1.1%, HSBC +0.9%
Other news: GTAT +21.5% (seeing reports that co's first bankruptcy hearing has been scheduled for Thursday), SCOK +11.7% (issues update on construction and financing of underground Syngas Project), WYY +8.6% (receives 4 new federal contract awards; contract has period of performance of one year and total ~$2.7 mln), DRL +6.7% (disclosed the appointment of Nancy Reinhard as acting CFO), TST +5% (to acquire BoardEx for ~$21 mln), CMRX +4.9% (shows potential survival benefit in Adenovirus infection), PAH +3.7% (Pershing square disclosed a 26.1% active stake), TASR +3.7% (body camera momentum builds as adoption of AXON and EVIDENCE.com accelerates), OXGN +3% (announced first patient enrolled in Phase 1b/2 Study of Fosbretabulin combined with Pazopanib in patients with advanced recurrent ovarian cancer), MBLY +2.9% (ahead of TSLA event tomorrow), TKMR +2.5% (cont momentum/Ebola play), JCP +2.3% (ahead of anaylst day), ORAN +1.4% (in talks with other cos to create Netflix (NFLX) like streaming service, according to reports), BCRX +1.1% (present clinical trial results related to investigational drug RAPIVAB at the IDWeek Conference October 8-12)
Analyst comments: COTY +4.2% (upgraded to Neutral from Sell at B. Riley & Co), GLUU +2.3% (upgraded to Buy from Hold at The Benchmark Company), CMI +0.9% (initiated with a Buy at Stifel), LEAF +0.9% (upgraded to Outperform from Neutral at Macquarie)
Gapping down
In reaction to disappointing earnings/guidance: TILE -17.9%, (announces expansion of credit facility, planned bond redemption, share repurchase program ), SAVE -3.2%, (co sees Q3 adjusted operating margin in lower half of previous guidance range) MON -1.6%, RPM -1%, ASX -0.8%,.
Other news: RDY -4% (weak markets in India overnight), SAP -3.5% (reports suggesting job freeze until 2015 ), ICPT -3.2% (co decides not to present FLINT data at AASLD), RIO -2.1% (may still go after a defense deal with Anglo American (AAUKY), according to reports), INFY -1.5% (weak markets in India overnight), ALU -1.1% (still checking), GSK -0.8% (corruption allegations, according to reports out intraday), AZN -0.8% (may be in sympathy with GSK)
Analyst comments: SSNI -2.3% (downgraded to Neutral from Buy at Goldman), GPRO -2.2% (downgraded to Neutral from Overweight at Piper Jaffray), ARP -1.6% (initiated with a Mkt Perform at Raymond James)
Gapping up/down: SIMO +15% and CAMP +7% after earnings, FEYE +6% after new partnerships; GMCR +2% on upgrade at GS; SODA and TCS -15% after earnings/guidance; LVS -3% after dg Price: null Change: null
Gapping up
In reaction to strong earnings/guidance: SIMO +14.9%, CAMP +7.2%, ISCA +4.9%, NLNK +1.9%, IDT +0.6%
Select Ebola related names showing strength: CMRX +3.9%, TKMR +3.4%, LAKE +2.8%
Other news: GTAT +15% (modest retracement following yesterday's massive decline), MAGS +15% (receives $8.2 mln of new orders; majority of the contracts are for expansions, changes and upgrades of existing homeland security installations in Israel), XCO +10.6% (announces sale of interests in Compass Production Partners), BCLI +9% (FDA grants fast track designation to NurOwn for the treatment of ALS), OXGN +8.3% (announced that data from the Phase 2 GOG186I study of fosbretabulin in combination with bevacizumab will be presented on November 9 at the International Gynecologic Cancer Society), GSAT +7.1% (issues statement in response to Kerrisdale Capital presentation), FEYE +5.8% (FireEye and SingTel partner to launch first managed defense solution; also, announced targeted attack protection for the Apple (AAPL) platform), BCRX +2.4% (announces late breaker presentation of OPuS-1 Phase 2 Trial results at the 23rd EADV Congress will be present Oct 11), ADHD +2.3% (after yesterday's 57% decline), ACHN +1.8% (disclosed it entered into a Master Security Agreement for a $1,000,000 Capital Expenditure Line of Credit), SBLK +1.6% (collected $8.016 mln from the sale of its claim against PAN OCEAN), REGN +1.3% (EYLEA (aflibercept) Injection received FDA approval for macular edema following retinal vein occlusion), PSTI +1.3% (wins cell therapy patent case in Europe; European Patent Office confirms validity of amended claims )
Analyst comments: ADHD +2.3% (upgraded to Outperform at FBR Capital), NDLS +2.1% (upgraded to Buy from Hold at Jefferies), AUY +2.1% (upgraded to Neutral from Underweight at HSBC Securities), GMCR +1.9% (initiated with a Buy at Goldman), KPTI +1.1% (initiated with a Outperform at Wedbush), IP +1.1% (upgraded to Buy from Neutral at BofA/Merrill), CCK +0.7% (upgraded to Outperform from Neutral at Macquarie)
Gapping down
In reaction to disappointing earnings/guidance: SODA -15.1%, TCS -14.6%, EZPW -13.6%, CBK -11.8%, AEGN -9.3%, AGCO -8.7%
Notable EU names showing weakness: ORAN -2.2%, DB -2.1%, NOK -2%, NBG -1.8%, RCL -1.2%, CCL -1.1%, AZN -1.1%, UBS -1.1%, LYG -0.8%, CS -0.8%
Other news: KOS -6.1% (announces secondary public offering of 15 mln common shares), BBEP -5.3% (announces public offering of 14 mln common units), END -5.3% (announced the appointment of a Chief Restructuring Officer), IBIO -4.7% (files for sale of up to 23,418,172 shares of common stock by Aspire Capital Fund), CNHI -4.3% (in sympathy with AGCO earnings), KCAP -3.8% (commences 3 mln share public offering), DYN -2.1% (launched 22.5 mln share common stock and 4 mln share mandatory convertible preferred stock offerings), NRP -2% (prices 8.5 mln common units at $12.02 per common unit), OTIV -1.6% (filed for $50 mln mixed securities shelf offering), BUD -1.6% (still checking), MBLY -1.4% (cont weakness), NUS -1% (following afternoon strength on volume)
Analyst comments: LVS -3.1% (downgraded to Hold from Buy at Deutsche Bank), URI -2.7% (downgraded to Neutral from Buy at BofA/Merrill), DE -2.6% (downgraded to Underperform from Neutral at BofA/Merrill), SAN -1.4% (downgraded to Reduce from Neutral at Nomura), CMI -1.3% (downgraded to Neutral from Buy at BofA/Merrill), ATI -1.2% (downgraded to Hold from Buy at KeyBanc Capital Mkts), USB -0.8% (downgraded to Mkt Perform from Strong Buy at Raymond James )
Gapping up/down: GPN +5% after earnings, WLT +6% on M&A spec, DTV +1.5% after renewed Sunday Ticket deal, TWTR +2% on upgrade at JPM; CREE -13% and AGU -5.5% after earnings/guidance, JPM -1% after dg at UBS Price: null Change: null
Gapping up
In reaction to strong earnings/guidance: GPN +5.4%, DRI +0.8%
M&A news: WLT +5.8% (may be an acquisition target by BHP (BHP), according to reports)
Other news: ESPR +33.4% (announces positive top-line Phase 2b results for ETC-1002, an investigational therapy for patients with hypercholesterolemia ), RLD +21.9% (Starboard raises stake to 9.9% and delivered a letter to the Board proposing to acquire the company for $12 per share), ARIA +10.2% (announces AP26113 has received Breakthrough Therapy designation by the FDA), LEU +8.8% (elects Williams as Chairman; begins process for CEO Transition; Chief Restructuring Officer John Castellano named interim CEO; John Welch to step down later this month), BTU +7% (WLT peer, may be in sympathy), DRL +6.2% (provided an update on status of its capital plan: co maintains readily available liquidity sources of ~$1 bln), SPEX +5.4% (cont momentum), GRMN +5% (announces Honda (HMC) has selected Garmin as the navigation provider for future Civic and CR-V models in Europe, Russia and South America), NBG +3.8% (still checking), TSLA +3.6% (Elon Musk tweets 'About time to unveil the D and something else'; suggesting Model D introduction on Oct 9), DTV +1.4% (Co and NFL extended and expanded DIRECTV's exclusive rights to carry NFL SUNDAY TICKET), ARG +1.3% (to increase argon prices by up to 15%, effective November 1 or as contracts permit), QIHU +1.1% (announces $200 mln Share Repurchase Plan), TKMR +1% (ebola play that was +18% yesterday)
Analyst comments: NDAQ +4.4% (upgraded to Buy from Hold at Deutsche Bank), ADSK +3.3% (upgraded to Outperform from Mkt Perform at Cowen), AKS +2.9% (upgraded to Buy from Hold at Deutsche Bank), TWTR +2.3% (upgraded to Overweight from Neutral at JP Morgan), JBLU +2% (upgraded to Mkt Perform from Underperform at Raymond James), RUBI +1.6% (initiated with a Buy at B. Riley & Co), P +1.5% (upgraded to Buy at Topeka Capital Markets), THRM +0.9% (upgraded to Outperform from Mkt Perform at Barrington Research ), ICE +0.7% (upgraded to Buy from Hold at Deutsche Bank), EXXI +0.7% (upgraded to Buy from Neutral at Guggenheim), BMS +0.7% (upgraded to Neutral from Underperform at BofA/Merrill), HBI +0.6% (initiated with a Outperform at Credit Suisse), VLO +0.5% (initiated with a Outperform at RBC Capital Mkts), BAC +0.5% (upgraded to Buy from Neutral at UBS)
Gapping down
In reaction to disappointing earnings/guidance: CREE -12.9%, AGU -5.5%, STZ -2.9%
Other news: WILN -13.1% (commenced litigation against several companies), TWI -8.7% (light volume, may be attributed to AGU outlook), NLNK -5.7% (announced appointment of Jack Henneman as Chief Financial Officer following departure of Gordon H. Link, Jr.), DNDN -5.2% (still checking), PTLA -3.6% (Portola Pharma files for 10 mln share common stock shelf offering; commenced an underwritten public offering of shares of its common stock and expects to raise gross proceeds of approximately $160,000,000), GPRO -2.5% (cont pre-mkt vol activity), RDUS -1.7% (announces proposed public offering), RVNC -1.5% (announced expected delay in results from Phase 3 study of RT001 for the treatment of lateral canthal (crow's feet) lines), MRD -1.5% (filed for ~27.8 mln share common stock offering by selling shareholders), POT -1% (following AGU earnings)
Analyst comments: DNDN -5.2% (target cut to $1 from $2 at Citi), ENPH -2.4% (downgraded to Neutral from Buy at BofA/Merrill), JPM -1% (downgraded to Neutral from Buy at UBS), MSI -0.7% (downgraded to Neutral from Buy at Citigroup), X -0.5% (downgraded to Hold from Buy at KeyBanc Capital Mkts), ETN -0.5% (downgraded to Perform from Outperform at Oppenheimer)
Gapping up/down: WAG +2% after earnings, MOVE +37% after merger news, TASR +4% on London Police camera news, AA +1% on upgrade; DWA -9% on downplay of takeover chatter, miners trading lower, CRR -1% on dg Price: null Change: null
Gapping up
In reaction to strong earnings/guidance: SNX +8.1%, (also initiates quarterly cash dividend of $0.125 per common share), SCOK +7.7%, WAG +2.3%, RBS +2.1%, CTAS +1.1%, HTGC +0.8%, (on track to achieve annual new commitments of approximately $700-$850 million for 2014)
M&A news: MOVE +37% (to be acquired by News Corp (NWSA) for $21 per share), DLIA +25% (announces review of strategic alternatives; received several inquiries from third parties regarding potential acquisition of the company), MAS +7.2% (announces strategic initiatives; Co to spin-off installation and other services segment, initiate share repurchase program and reduce corporate expense), SMPL +4.9% (HomeStreet to merge with Simplicity Bancorp; Simplicity stockholders to receive one share of HomeStreet common stock for each share of Simplicity common stock)
Other news: WYY +17.8% (received two new Task Orders from federal agencies under a recently awarded Federal Government Blanket Purchase Agreement), VIMC +13.8% (announces $12.4 mln contract win in Taiyuan City of Shanxi Province), CPRX +13.7% (announces positive top-line Phase 3 Data From Pivotal Firdapse clinical trial in patients with Lambert-Eaton Myasthenic Syndrome), ACST +11.5% (announces 'Positive' top-line Pharmacokinetic results), CRNT +10.8% (receives follow-on orders from a global Tier 1 operator serving 20 countries across Asia and Africa), CANF +9.6% (USPTO issues Can-Fite patent for CF102 in the treatment of liver regeneration and function following surgery), EBAY +8.9% (eBay to separate eBay and PayPal into independent publicly traded companies in 2015), BLDP +8.2% (receives ElectraGen fuel cell system order for deployments in Digicel network), CNET +7.8% (Co's Liansuo.com signs 12 new clients following Guangzhou Franchise Exhibition), HTZ +5.4% (still checking), TASR +3.9% (selected by the London Metropolitan Police Service to provide another 500 AXON cameras), PLUG +3.4% (move attributed to positive blog mention, also peer BLDP received large order), RWLK +2.9% (cont momentum post IPO), MCP +2.4% (announces that its expanded leach system has now been placed into service at its Mountain Pass, California Facility), CTRP +2.3% (Priceline (PCLN) disclosed a 5.84% active stake in 13D filing) MBLY +2.3% (still checking), RADA +2.2% (following yesterday's 35% move higher), GPRO +1.9% (following 11% upside move yesterday), HIMX +1.8% (cont momentum), EXXI +1.5% (provides operations update: Q1 production expected at mid-point of guidance; West Delta horizontal program continues to deliver with three new wells brought online ), Z +1.4% (MOVE peer), KR +1.2% (positive commentary on Monday's Mad Money), SDRL +1.1% (still checking, may be just bouncing — shares have sold off significantly in recent weeks), AAPL +0.8% (iPhone 6 & iPhone 6 Plus available in China on Friday, October 17)
Analyst comments: TK +6.6% (upgraded to Buy from Hold at Deutsche Bank), MLNX +3.3% (upgraded to Overweight from Neutral at Piper Jaffray), RMBS +2.8% (attributed to positive Jefferies comments suggesting RMBS as Apple Pay beneficiary), EPAM +1.7% (initiated with a Positive at Susquehanna), AA +1% (upgraded to Buy from Neutral at BofA/Merrill), NWBI +1% (upgraded to Outperform from Neutral at Boenning & Scattergood), TM +0.8% (upgraded to Overweight from Neutral at JP Morgan), FB +0.7% (target raised to $95 from $90 at Evercore), LMT +0.5% (upgraded to Buy from Hold at Stifel)
Gapping down
In reaction to disappointing earnings/guidance: PDFS -17.8%, JRJC -8%, TA -5.2%, SANW -4.1%
M&A news: DWA -9.1% (Softbank (SFTBY) merger talks with DWA being donwplayed, according to reports; also reports indicate SFTBY may purchase Legendary Pictures)
Other news: MTL -13.3% (cont bankruptcy speculation), TSL -3% (announces the offering of ~7 mln American Depositary Shares), FDUS -2.2% ( announces commencement of public offering of common stock), WUBA -1.8% (still checking), F -0.9% (following late weakness on comments from Investor Day — says it will miss its 2014 pretax profit goal of $6 bln), SVU -0.9% (announced the discovery of malware on some of its point of sale systems; protective technology believed to have limited the risk of data theft)
Analyst comments: ARMH -2.1% (downgraded to Underperform from Mkt Perform at Bernstein), CRR -1% (downgraded to Underweight from Equal-Weight at Morgan Stanley), SGEN -1% (downgraded to Underperform from Neutral at BofA/Merrill), K -0.9% (downgraded to Underweight from Equal-Weight at Morgan Stanley)
Gapping up/down: AMBI +88%, DWA +26%, ATHL +24%, TIBX +21% and AMAG +15% on M&A related news; HIMX +2% on upgrade; EU financials, select energy and metal names trading lower; AVY -1% on dg at JPM Price: null Change: null
Gapping up
In reaction to strong earnings/guidance: RCON +7.2%, LAS +2.3%, KOOL +1.7%, CALM +1.2%, ADP +0.7%
M&A news: AMBI +87.8% (Daiichi Sankyo (DSNKY) to acquire Ambit Biosciences for $15 per share in cash through a tender offer), DWA +26.4% (Softbank (SFTBY) is in discussions to purchase DWA, according to reports, Variety discusses comments from sources that chances of Softbank (SFTBY) acquiring DWA are slim), ATHL +24.6% (Encana (ECA) to acquire all of the issued and outstanding shares of common stock of Athlon by means of an all-cash tender offer for $58.50 per share), TIBX +21% (to be acquired by Vista Equity Partners for $24.00 per share in cash), AMAG +15.4% (to acquire Lumara Health for $600 mln in cash and $75 mln in stock and additional contingent consideration of up to $350 mln)
Other news: EXEL +18.6% (announces positive results from Phase 3 pivotal trial of Cobimetinib in combination with Vemurafenib in patients with BRAF V600 Mutation-positive advanced melanoma), ALIM +16.6% (provides details on FDA approval Of ILUVIEN as the first long-term treatment for diabetic macular edema), ECYT +10.2% (Phase 2b TARGET trial results show improved survival in Adenocarcinoma non-small cell lung cancer patients treated with Endocyte's Vintafolide), PSDV +9.8% (reports approval of ILUVIEN for diabetic macular edema; triggers $25 mln milestone payment from Alimera Sciences (ALIM)), CYTR +7.9% (receives multiple FDA Orphan Drug designations for Aldoxorubicin for the treatment of Glioblastoma), PE +5.6% (still checking), ACST +4.1% (reports successful CaPre Phase II TRIFECTA results proving statistically significant improvements in triglycerides & non-HDL-C), ARIA +4% (announces updated clinical results for AP26113, study results show sustained anti-tumor activity), SGEN +3.9% (Seattle Genetics and Takeda (TKPYY) announce positive data from Phase 3 AETHERA clinical trial of ADCETRIS), KMDA +3.3% (announces second extension of Strategic Agreement with Baxter (BAX)), ISR +3.1% (still checking), DATE +3% (declared a special one-time cash dividend of $0.4467 per ordinary share, or $0.67 per American Depositary Share), WEX +1.4% (positive commentary on Friday's Mad Money)
Analyst comments: HIMX +2.2% (upgraded to Buy from Hold at Craig Hallum), SAH +1.4% (upgraded to Overweight from Underweight at Morgan Stanley), BIDU +0.7% (upgraded to Buy from Neutral at UBS)
Gapping down
In reaction to disappointing earnings/guidance: ELGX -2%, FGP -1.4%
Select EU financial related names showing weakness: HSBC -2.1%, NBG -2%, BCS -1.5%, LYG -1.4%, ING -1.3%, DB -1.1%
Select metals/mining stocks trading lower: VALE -3.6%, CLF -2.4%, X -2.1%, RIO -1.8%, BHP -1.5%
Select oil/gas related names showing early weakness: PBR -3.9%, CEO -2.2%, TOT -1%, BP -0.5%.
Other news: NXTD -8.3% (reports Wocket is in production), JNS -1.7% (slight pull back following Friday's 40%+ move higher), OLBK -1.6% (announces plans for branch consolidation), BBRY -1.3% (still checking), TSLA -1.3% (WSJ discusses that many in China are still skeptical regarding TSLA China stations), AAPL -1.2% (several stories out over weekend, may be attributed to news that AAPL may be accused of illegal Irish tax deals)
Analyst comments: EMKR -3.2% (downgraded to Hold from Buy at Needham), AVY -1.2% (downgraded to Neutral from Overweight at JP Morgan), DE -0.5% (target lowered to $95 from $98 at Credit Suisse), DRC -0.5% (downgraded to Neutral from Buy at Guggenheim)
Gapping up/down: SLXP +8% and CF +7% on M&A news; miners trading higher, TKMR +10% on Ebola collaboration news; ASNA -11% and KMX -6% after earnings, Tax inversion names trading lower, DKS -6% after dg Price: null Change: null
Gapping up
In reaction to strong earnings/guidance: SUPN +9.5%, MM +1.7%, (also, to acquire Nexage for ~$107.5 mln)
M&A news: SLXP +8.2% (Allergan (AGN) plans to reject offer from Actavis (ACT) and may now bid for SLXP itself, according to reports), CF +7.2% (Yara ASA confirms discussions with CF (CF) regarding potential merger of equals)
Select metals/mining stocks trading higher: HMY +3.4%, GOLD +2.3%, SLW +1.9%, AU +1.9%, GG +1.6%, ABX +1.4%, NEM +1.4%, GDX +1.4%, GLD +1.2%, RIO +0.9%, BHP +0.8%
Other news: SYN +36% (still checking), NXTD +24.5% (cont momentum higher), TTOO +18.1% (announced FDA approval of first direct blood test for detection of five yeast pathogens that cause bloodstream infections), RWLK +11% (announces reimbursement coverage by major German insurance company ), SAEX +9.9% (announced $40 mln of new project awards), TKMR +9.6% (is collaborating with an international consortium to provide an RNAi based investigational therapeutic for expedited clinical studies in West Africa), NAVB +7.1% (Awarded $1.67 mln Fast Track NIH SBIR Grant for Evaluation of Lymphoseek in Cervical Cancer), JRJC +6.6% (entered into a strategic partnership agreement with Zhongshan Securities), ECYT +3.6% (announces late-breaking abstract presentation on randomized, phase II trial comparing vintafolide versus vintafolide plus docetaxel, versus docetaxel alone in second-line treatment of folate-receptor-positive non-small cell lung cancer patients at the European Society for Medical Oncology Conference), MBLY +3.4% (favorable commentary on Monday's Mad Money), HLF +2.7% (following 12%+ move lower on some chatter that Icahn is unwinding his position; after the close Gasparino tweeting that sources say Icahn has not sold any of his HLF stake), DRL +2.2% (co stated its remains confident in the rule of law and that it will prevail' as DRL vs. Hacienda trial concluded), CNET +1.9% (cont momentum), PHG +1.7% (establishes two companies in Lighting solutions and in HealthTech; sees 2H adjusted EBITA slightly below same period last year), MGA +1.7% (expands in India; targeting start of volume production in 2015), DRI +1.4% (issues open letter to shareholders; recommends darden shareholders vote 'for all' on the BLUE Proxy Card ), ASTM +1.1% (Great Point Partners discloses 9.99% stake in 13G filing), LDOS +1% (awarded contract by Naval Medical Logistics Command)
Analyst comments: SGMO +4% (initiated with a Buy at Jefferies), NRG +1.8% (resumed with a Buy at Deutsche Bank), BKU +1.6% (resumed with a Outperform at Wells Fargo), FOE +1.2% (upgraded to Buy from Hold at KeyBanc Capital Mkts), FRC +1% (resumed with a Outperform at Wells Fargo)
Gapping down
In reaction to disappointing earnings/guidance: ASNA -11.1%, ALCS -6.9%, KMX -6.3%
Other news: MTL -28.4% (continued bankruptcy concerns), AVNR -7.5% (announced offering of $200 mln of common stock), GEL -4.9% (announces public offering of 4.0 mln common units), ALIM -2.8% (disclosed sales agreement to issue and sell $35 mln common stock), TSLA -1.8% (cont weakness), YHOO -1.7% (cont weakness post BABA IPO), BABA -1.6% (cont weakness post IPO), SYY -1.5% (may face antitrust lawsuit over US Foods deal, according to reports), TOT -1.4% (trading lower in Europe following news out yesterday afternoon), HCLP -1.4% (unfavorable commentary on Monday's Mad Money)
Analyst comments: DKS -5.9% (downgraded to Mkt Perform from Outperform at William Blair ), ONNN -3.1% (downgraded to Neutral from Overweight at JP Morgan), BBBY -1.3% (downgraded to Mkt Perform from Outperform at William Blair), CLX -1.2% (downgraded to Neutral from Buy at Citigroup), GMAN -0.6% (downgraded to Hold from Buy at Canaccord Genuity)
